Anna Balducci
University of Bologna
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Anna Balducci.
European Heart Journal | 2008
Alessandro Giardini; Anna Balducci; Salvatore Specchia; Gaetano Gargiulo; Marco Bonvicini; Fernando M. Picchio
AIMS We sought to assess the effects of sildenafil on exercise capacity and haemodynamic response to exercise in Fontan patients. METHODS AND RESULTS We prospectively studied 27 patients with Fontan circulation (age 22.8 +/- 4.9 years). All patients underwent a baseline exercise test with non-invasive measurement of cardiac index (CI) and pulmonary blood flow (PBF) index, and peak exercise oxygen uptake (VO(2)). After the baseline test, patients were randomly assigned to receive either a single 0.7 mg/kg body weight oral dose of sildenafil citrate (n = 18) or no treatment (control group, n = 9). After 1 h of rest, all patients performed a second exercise test. All patients completed the study protocol. The dose of sildenafil ranged from 25 to 50 mg. The change in peak VO(2), the primary endpoint, was greater in the sildenafil group (9.4 +/- 5.2%) than in the control group (0.3 +/- 4.1%, P < 0.05). Sildenafil increased rest and peak exercise PBF index (P < 0.01 and P < 0.05 vs. control group, respectively), as well as rest and peak exercise CI (P < 0.001 and P < 0.05 vs. control group, respectively), without altering rest or peak exercise transcutaneous arterial blood oxygen saturations (P > 0.05 vs. control group for both). No patient reported serious adverse events after sildenafil. CONCLUSION In Fontan patients, oral administration of a single dose of sildenafil improves exercise capacity and haemodynamic response to exercise.
Congenital Heart Disease | 2013
Marianna Fabi; Gabriella Testa; Valentina Gesuete; Anna Balducci; Luca Ragni
Takotsubo cardiomyopathy, or broken heart syndrome, is characterized by transient left ventricular dysfunction associated to chest pain, elevation of cardiac enzymes, and electrocardiographic changes, mimicking an acute coronary syndrome, especially in older women after a physical or emotional stress. It is extremely infrequent in children as well as after infective stress. We described a celiac 4-year-old girl, following a gluten-free diet, who developed features of cardiac failure few days after episodes of acute diarrhea with fever. The patient was treated with oral anticongestive therapy and intravenous immunoglobulins, and she had a dramatic and rapid improvement; echocardiographic features normalized in 48 hours.
Cardiology Research and Practice | 2017
Elisabetta Mariucci; Andrea Donti; Luisa Salomone; Marta Marcia; Marta Guidarini; Roberto Formigari; Daniela Prandstraller; Anna Balducci; Gabriele Bronzetti; Marco Bonvicini
Background There are few data on the mechanism of recurrent neurological events after transcatheter closure of patent foramen ovale (PFO) in cryptogenic stroke or TIA. Methods We retrospectively reviewed PFO closure procedures for the secondary prevention of cryptogenic stroke/TIA performed between 1999 and 2014 in Bologna, Italy. Results Written questionnaires were completed by 402 patients. Mean follow-up was 7 ± 3 years. Stroke recurred in 3.2% (0.5/100 patients-year) and TIA in 2.7% (0.4/100 patients-year). Ninety-two percent of recurrent strokes were not cryptogenic. Recurrent stroke was noncardioembolic in 69% of patients, AF related in 15% of patients, device related in 1 patient, and cryptogenic in 1 patient. AF was diagnosed after the procedure in 21 patients (5.2%). Multivariate Coxs proportion hazard model identified age ≥ 55 years at the time of closure (OR 3.16, p=0.007) and RoPE score < 7 (OR 3.21, p=0.03) as predictors of recurrent neurological events. Conclusion Recurrent neurological events after PFO closure are rare, usually noncryptogenic and associated with conventional vascular risk factors or AF related. Patients older than 55 years of age and those with a RoPE score < 7 are likely to get less benefit from PFO closure. After transcatheter PFO closure, lifelong strict vascular risk factor control is warranted.
Giornale italiano di cardiologia | 2016
Gesuete; Marianna Fabi; Anna Balducci; Luca Ragni; Marco Bonvicini
Pulmonary embolism is an uncommon but potentially fatal disease in children, especially with congenital heart disease where pulmonary perfusion depends on caval flow. Anticoagulation is the mainstay of therapy for children with pulmonary embolism. However, thrombolytic therapy can also be considered. The outcome of pediatric pulmonary embolism is uncertain and needs further investigation. We suggest increased awareness and a high index of suspicion in the presence of suggestive clinical signs in high-risk patients in order to initiate prompt diagnostic imaging and treatment.
European Heart Journal | 2012
Michiel M. Winter; Teun van der Bom; Leonie C. S. de Vries; Anna Balducci; Berto J. Bouma; Petronella G. Pieper; Arie P.J. van Dijk; Mart N. van der Plas; Fernando M. Picchio; Barbara J.M. Mulder
International Journal of Cardiology | 2015
Teun van der Bom; Michiel M. Winter; Jennifer L. Knaake; Elena Cervi; Leonie S.C. de Vries; Anna Balducci; Paola G. Meregalli; Petronella G. Pieper; Arie P.J. van Dijk; Marco Bonvicini; Barbara J.M. Mulder; Berto J. Bouma
Italian Journal of Pediatrics | 2014
F. Vitali; Silvia Galletti; Arianna Aceti; Giulia Aquilano; Marianna Fabi; Anna Balducci; Giacomo Faldella
cardiology research | 2011
Marianna Fabi; Valentina Gesuete; Gabriella Testa; Anna Balducci; Fernando M. Picchio; Gaetano Gargiulo
Giornale italiano di cardiologia | 2010
Alessandro Corzani; Andrea Donti; Valentina Gesuete; Roberto Formigari; Gabriella Testa; Gabriele Bronzetti; Anna Balducci; Marianna Fabi; Marco Bonvicini; Fernando M. Picchio
Progress in Pediatric Cardiology | 2018
Silvia Favilli; Daniela Prandstraller; Gaia Spaziani; Giovanni Battista Calabri; Maristella Lombardi; Anna Balducci; Ugo Vairo